{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:10:33Z","timestamp":1789755033131,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AG072946"],"award-info":[{"award-number":["P30 AG072946"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RO1 AG061111"],"award-info":[{"award-number":["RO1 AG061111"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tjpad.2026.100669","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:11:27Z","timestamp":1789477887000},"page":"100669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-8403","authenticated-orcid":false,"given":"E. Pinar","family":"Coskun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-1834","authenticated-orcid":false,"given":"Justin","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8285-9618","authenticated-orcid":false,"given":"Lauren","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9748","authenticated-orcid":false,"given":"Christopher J.","family":"McLouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Abner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-6400","authenticated-orcid":false,"given":"Linda J.","family":"Van Eldik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-1265","authenticated-orcid":false,"given":"Peter T.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Jicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100669_bib0001","series-title":"FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Application","year":"2023"},{"key":"10.1016\/j.tjpad.2026.100669_bib0002","unstructured":"(FDA), U.S.F.a.D.A., FDA approves treatment for adults with Alzheimer\u2019s disease. 2024."},{"issue":"2","key":"10.1016\/j.tjpad.2026.100669_bib0003","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimer's Dement: Transl Res Clin Interv"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.tjpad.2026.100669_bib0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.0000000000207438","article-title":"Implications of the approval of Lecanemab for Alzheimer Disease patient care: incremental step or paradigm shift?","volume":"101","author":"Knopman","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100669_bib0006","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.tjpad.2026.100669_bib0007","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","article-title":"Mixed brain pathologies account for most dementia cases in community-dwelling older persons","volume":"69","author":"Schneider","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100669_bib0008","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/brain\/awad059","article-title":"Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated","volume":"146","author":"Robinson","year":"2023","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100669_bib0009","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","article-title":"Prevalence and clinical phenotype of quadruple misfolded proteins in older adults","volume":"77","author":"Karanth","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cger.2022.07.005","article-title":"Neuropathology of the common forms of dementia","volume":"39","author":"Mehta","year":"2023","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0011","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/alz.13447","article-title":"Identifying individuals with non-Alzheimer's disease co-pathologies: a precision medicine approach to clinical trials in sporadic Alzheimer's disease","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trci.2016.09.002","article-title":"Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development","volume":"3","author":"Rabinovici","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100669_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jnen\/nlaa014","article-title":"Concordance of clinical Alzheimer diagnosis and neuropathological features at autopsy","volume":"79","author":"Gauthreaux","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100669_bib0014","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer's disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100669_bib0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-023-02631-8","article-title":"Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab","volume":"146","author":"VandeVrede","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100669_bib0016","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-201213","article-title":"Alzheimer's Disease neuropathological comorbidities are common in the younger-old","volume":"79","author":"Beach","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100669_bib0018","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/156720512801322591","article-title":"University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology","volume":"9","author":"Schmitt","year":"2012","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100669_bib0019","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bpa.12505","article-title":"Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi","volume":"28","author":"Smith","year":"2018","journal-title":"Brain Pathol"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100669_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jnen\/nly049","article-title":"The Revised National Alzheimer's Coordinating Center's neuropathology form-available data and new analyses","volume":"77","author":"Besser","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100669_bib0022","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100669_bib0023","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","article-title":"Neuropathological consensus criteria for the evaluation of lewy pathology in post-mortem brains: a multi-centre study","volume":"141","author":"Attems","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100669_bib0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100669_bib0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-014-0082-1","article-title":"Prevalence of mixed pathologies in the aging brain","volume":"6","author":"Rahimi","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100669_bib0027","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/aww224","article-title":"TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia","volume":"139","author":"James","year":"2016","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100669_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae435","article-title":"Evaluating clinical meaningfulness of anti-beta-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease","volume":"6","author":"Aljuhani","year":"2024","journal-title":"Brain Commun"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0029","article-title":"Enriching the design of Alzheimer's disease clinical trials: application of the polygenic hazard score and composite outcome measures","volume":"6","author":"Banks","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14264","article-title":"ADNI Biomarker Core: a review of progress since 2004 and future challenges","volume":"21","author":"Shaw","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100669_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102739","article-title":"Fluid-based biomarkers for neurodegenerative diseases","volume":"108","author":"Cao","year":"2025","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100669_bib0032","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/cells12040597","article-title":"TDP-43 proteinopathy specific biomarker development","volume":"12","author":"Cordts","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0033","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100669_bib0034","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/alz.12814","article-title":"Dementia with lewy bodies: impact of co-pathologies and implications for clinical trial design","volume":"19","author":"Toledo","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100669_bib0036","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100669_bib0037","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","article-title":"CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14202","article-title":"Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy","volume":"21","author":"Wolk","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0039","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","article-title":"Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies","volume":"8","author":"Magalhaes","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100669_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab076","article-title":"White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline","volume":"3","author":"Vemuri","year":"2021","journal-title":"Brain Commun"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100669_bib0041","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/biomedicines11020335","article-title":"The future of precision medicine in the cure of Alzheimer's disease","volume":"11","author":"Arafah","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.tjpad.2026.100669_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113337","article-title":"The road to precision medicine: eliminating the \u201cone size fits all\u201d approach in Alzheimer\u2019s disease","volume":"153","author":"Behl","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100669_bib0043","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","article-title":"Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability","volume":"4","author":"Therriault","year":"2024","journal-title":"Nat Aging"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100669_bib0044","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100669_bib0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.14283\/jpad.2022.50","article-title":"Tackling a major deficiency of diversity in Alzheimer's disease therapeutic trials: an CTAD Task Force report","volume":"9","author":"Raman","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"Suppl 2","key":"10.1016\/j.tjpad.2026.100669_bib0046","doi-asserted-by":"crossref","first-page":"709","DOI":"10.18865\/ed.30.S2.709","article-title":"Perceived impediments to completed brain autopsies among diverse older adults who have signed a uniform anatomical gift act for brain donation for clinical research","volume":"30","author":"Glover","year":"2020","journal-title":"Ethn Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100669_bib0047","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12737","article-title":"Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials","volume":"19","author":"Langbaum","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0048","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40900-025-00689-0","article-title":"Overcoming barriers to implementation of patient engagement in clinical trials: feasibility testing of an embedded study","volume":"11","author":"Castonguay","year":"2025","journal-title":"Res Involv Engag"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100669_bib0049","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: a VASCOG statement","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100669_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-020-02235-6","article-title":"Brain arteriolosclerosis","volume":"141","author":"Blevins","year":"2021","journal-title":"Acta Neuropathol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:45:20Z","timestamp":1789753520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726001937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2274580726001937"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100669","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100669"}}